



WHAT IS CLAIMED IS:

1. A compound represented by formula I:



- 5 wherein  
 $R_1$  is C<sub>1-6</sub> alkyl;  
 $R_2$  is H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl, OC<sub>1-6</sub> alkyl or C(O)C<sub>1-6</sub> alkyl;  
 $R_3$  is H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl, OC<sub>1-6</sub> alkyl or C(O)C<sub>1-6</sub> alkyl,  
 10 or aralkyl;  
 X is C or N;  
 Y is H, halogen, C<sub>1-6</sub> alkyl, CN or CF<sub>3</sub>;  
 Z is NHR<sub>3</sub> or F;
- 15 or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.
2. A compound as defined in claim 1 wherein  $R_2$  is C<sub>3-8</sub>  
 20 cycloalkyl.
3. A compound represented by the formula



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.

4. A pharmaceutical composition which is comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.

5. A pharmaceutical composition which is produced by combining a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.

6. A method of treating a cytokine mediated disease in a mammal, comprising administering to a mammalian patient in need of such treatment an amount of a compound as described in claim 1 in an amount which is effective to treat said cytokine mediated disease.

7. A method of treating inflammation in a mammalian patient in need of such treatment, which is comprised of administering to said patient an anti-inflammatory effective amount of a compound as described in claim 1.

8. A method in accordance with claim 6 wherein the cytokine mediated disease is rheumatoid arthritis, osteoarthritis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic

arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis or acute synovitis.

5           9.     A method in accordance with claim 6 wherein  
the cytokine mediated disease is rheumatoid arthritis, rheumatoid  
spondylitis, osteoarthritis, gouty arthritis, sepsis, septic shock, endotoxic  
shock, gram negative sepsis, toxic shock syndrome, adult respiratory  
distress syndrome, cerebral malaria, chronic pulmonary inflammatory  
disease, silicosis, pulmonary sarcosis, bone resorption diseases,  
10    reperfusion injury, graft v. host rejection, allograft rejection, fever,  
myalgia due to infection, cachexia secondary to infection or malignancy,  
cachexia secondary to acquired immune deficiency syndrome (AIDS),  
AIDS related complex (ARC), keloid formation,  
scar tissue formation, Crohn's disease, ulcerative colitis or pyresis.

15           10.    A method of treating osteoporosis in a mammalian  
patient in need of such treatment, which is comprised of administering to  
said patient an amount of a compound as described in claim 1 which is  
effective to treat osteoporosis.

20           11.    A method of treating bone resorption in a mammalian  
patient in need of such treatment, which is comprised of administering to  
said patient an amount of a compound as described in claim 1 which is  
effective to treat bone resorption.

25           12.    A method of treating Crohn's disease in a mammalian  
patient in need of such treatment which is comprised of administering to  
said patient an amount of a compound as described in claim 1 which is  
effective to treat Crohn's disease.

30           13.    A process for making a pharmaceutical composition  
comprising combining a compound of Claim 1 and a pharmaceutically  
acceptable carrier.